TR200102109T2 - Ras-farnesiltransferazı inhibitörü ve sülfobütileter-7-ß-siklodekstrin veya 2-hidroksipropil-ß-siklodekstrin kompleksi ve metod. - Google Patents
Ras-farnesiltransferazı inhibitörü ve sülfobütileter-7-ß-siklodekstrin veya 2-hidroksipropil-ß-siklodekstrin kompleksi ve metod.Info
- Publication number
- TR200102109T2 TR200102109T2 TR2001/02109T TR200102109T TR200102109T2 TR 200102109 T2 TR200102109 T2 TR 200102109T2 TR 2001/02109 T TR2001/02109 T TR 2001/02109T TR 200102109 T TR200102109 T TR 200102109T TR 200102109 T2 TR200102109 T2 TR 200102109T2
- Authority
- TR
- Turkey
- Prior art keywords
- ras
- cyclodextrin
- complex
- sulfobutylether
- hydroxypropyl
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Nanotechnology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Bir ras-farnesiltransferazi inhibitörü kompleksi olup, formül (I)'i havi ras-farnesiltransferazi inhibitörünü veya bunun farmasötik yönden kabul edilebilir bir tuzunu ve sülfobütileter-7- -siklodekstrini veya 2-hidroksipropil- -siklodekstrini ihtiva eder, ve burada n 0 veya 1'dir; R1 C1, Br, fenil, piridil veya siyanodan seçilir; R2 aralkildir; R3 sayica düsük karbonlu alkil, aril, veya ikameli/katkili aril veya heterosiklodan seçilir; Z1 CO, SO2, CO2, SO2NR5 den seçilir ve burada R5 hidrojen, sayica düsük karbonlu alkil veya ikameli/katkili alkilden seçilir. Bu kompleks ras-farnesiltrasferazi inhibitörünün beklenmedik derecede yüksek olan bir suda erime kabiliyetini ortaya koyar ve kansere yakalanmis olan insanlara damar içine uygulanmaya uygundur. Kompleksin meydana getirilmesine yönelik bir metod da ortaya konulmaktadir. Ras-farnesiltransferazi inhibitörleri anti-tümör ajanlar olarak faydalidir.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11664799P | 1999-01-21 | 1999-01-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
TR200102109T2 true TR200102109T2 (tr) | 2001-12-21 |
Family
ID=22368422
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TR2001/02109T TR200102109T2 (tr) | 1999-01-21 | 1999-12-21 | Ras-farnesiltransferazı inhibitörü ve sülfobütileter-7-ß-siklodekstrin veya 2-hidroksipropil-ß-siklodekstrin kompleksi ve metod. |
Country Status (33)
Country | Link |
---|---|
US (1) | US6218375B1 (tr) |
EP (1) | EP1143796A4 (tr) |
JP (1) | JP2002535253A (tr) |
KR (1) | KR100708360B1 (tr) |
CN (1) | CN1219517C (tr) |
AR (1) | AR022323A1 (tr) |
AU (1) | AU772204B2 (tr) |
BG (1) | BG105666A (tr) |
BR (1) | BR9916566A (tr) |
CA (1) | CA2359646C (tr) |
CO (1) | CO5160253A1 (tr) |
CZ (1) | CZ20012601A3 (tr) |
EE (1) | EE200100382A (tr) |
GE (1) | GEP20043214B (tr) |
HK (1) | HK1038865A1 (tr) |
HU (1) | HUP0105160A3 (tr) |
ID (1) | ID30139A (tr) |
IL (1) | IL144025A (tr) |
LT (1) | LT4893B (tr) |
LV (1) | LV12712B (tr) |
MY (1) | MY119700A (tr) |
NO (1) | NO20013585L (tr) |
NZ (1) | NZ511995A (tr) |
PE (1) | PE20001419A1 (tr) |
PL (1) | PL195280B1 (tr) |
RU (1) | RU2230062C2 (tr) |
SK (1) | SK9602001A3 (tr) |
TR (1) | TR200102109T2 (tr) |
TW (1) | TWI232752B (tr) |
UA (1) | UA67825C2 (tr) |
UY (2) | UY25986A1 (tr) |
WO (1) | WO2000042849A1 (tr) |
ZA (1) | ZA200104416B (tr) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI310684B (en) | 2000-03-27 | 2009-06-11 | Bristol Myers Squibb Co | Synergistic pharmaceutical kits for treating cancer |
JP2003063965A (ja) * | 2001-06-13 | 2003-03-05 | Otsuka Pharmaceut Factory Inc | 注射用シロスタゾール水性製剤 |
US6566347B1 (en) * | 2001-08-22 | 2003-05-20 | Duquesne University Of The Holy Ghost | Controlled release pharmaceutical |
AU2002359412A1 (en) * | 2001-11-13 | 2003-05-26 | Bristol-Myers Squibb Company | Process for the preparation of 3,7-disubstituted-2,3,4,5- tetrahydro-1h-1,4-benzodiazepine compounds |
KR100451485B1 (ko) | 2002-03-28 | 2004-10-06 | 주식회사종근당 | 푸마질롤 유도체 또는 그 염의 포접 화합물, 및 이를포함하는 약제학적 조성물 |
US6869939B2 (en) * | 2002-05-04 | 2005-03-22 | Cydex, Inc. | Formulations containing amiodarone and sulfoalkyl ether cyclodextrin |
US20040009972A1 (en) * | 2002-06-17 | 2004-01-15 | Ding Charles Z. | Benzodiazepine inhibitors of mitochondial F1F0 ATP hydrolase and methods of inhibiting F1F0 ATP hydrolase |
US7157446B2 (en) * | 2003-05-02 | 2007-01-02 | Bristol Myers Squibb Company | Complex of ras-farnesyltransferase inhibitor, a cyclodextrin, and ethanol |
US20070020299A1 (en) | 2003-12-31 | 2007-01-25 | Pipkin James D | Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid |
US20100204178A1 (en) | 2006-10-02 | 2010-08-12 | James Cloyd | Novel parenteral carbamazepine formulation |
BRPI0616447A2 (pt) * | 2005-09-30 | 2011-06-21 | Ovation Pharmaceuticals Inc | complexo de inclusão de carbamazepina-ciclodextrina, método de administrar e método de preparar o mesmo |
CN100503647C (zh) * | 2005-11-02 | 2009-06-24 | 南京师范大学 | 羟丙基-磺丁基-β-环糊精及其制备方法、分析方法以及在药学上的应用 |
TW200806284A (en) * | 2006-03-31 | 2008-02-01 | Alcon Mfg Ltd | Prenyltransferase inhibitors for ocular hypertension control and the treatment of glaucoma |
RU2009123536A (ru) * | 2006-11-21 | 2010-12-27 | Новартис АГ (CH) | Стабильные парентеральные составы, включающие ингибиторы pcb на основе бензодиазепина |
HUE037716T2 (hu) | 2008-10-22 | 2018-09-28 | Array Biopharma Inc | Szubsztituált pirazolo[l,5-a]pirimidin vegyületek mint TRK kináz inhibitorok |
AU2011258964B2 (en) | 2010-05-26 | 2015-04-16 | Neurophyxia B.V. | 2-iminobiotin formulations and uses thereof |
WO2012034038A2 (en) | 2010-09-09 | 2012-03-15 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Dual inhibitors of farnesyltransferase and geranylgeranyltransferase i |
EP2763681B1 (en) * | 2011-10-07 | 2017-08-16 | Pisces Therapeutics LLC | Malignant and non-malignant disease treatment with ras antagonists |
CN105194685A (zh) * | 2015-10-15 | 2015-12-30 | 重庆大学 | 磺胺脒的磺丁基醚-β-环糊精包合物及其粉针制剂 |
AU2016372396B2 (en) | 2015-12-16 | 2022-04-14 | Neurophyxia B.V. | 2-iminobiotin for use in the treatment of brain cell injury |
US10045991B2 (en) | 2016-04-04 | 2018-08-14 | Loxo Oncology, Inc. | Methods of treating pediatric cancers |
TN2018000335A1 (en) | 2016-04-04 | 2020-01-16 | Loxo Oncology Inc | Liquid formulations of (s)-n-(5-((r)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide |
ES2952056T3 (es) | 2016-05-18 | 2023-10-26 | Loxo Oncology Inc | Preparación de (s)-n-(5-((r)-2-(2,5-difluorofenil)pirrolidin-1-il)pirazolo[1,5-a]pirimidin-3-il)-3-hidroxipirrolidina-1-carboxamida |
JOP20190092A1 (ar) | 2016-10-26 | 2019-04-25 | Array Biopharma Inc | عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها |
US20210145816A1 (en) * | 2019-11-15 | 2021-05-20 | Cyclolab Cyclodextrin Research And Development Laboratory Ltd. | Pharmaceutical formulation of lonafarnib with a sulfobutylether beta-cyclodextrin |
AU2022414970A1 (en) * | 2021-12-15 | 2024-06-27 | Sillajen, Inc. | Pharmaceutical compositions comprising modified beta-cyclodextrins |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5630927A (en) * | 1979-08-24 | 1981-03-28 | Zeria Shinyaku Kogyo Kk | Stabilization of guaiazulene and its derivative |
US4371673A (en) * | 1980-07-21 | 1983-02-01 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Water soluble forms of retinoids |
US4727064A (en) * | 1984-04-25 | 1988-02-23 | The United States Of America As Represented By The Department Of Health And Human Services | Pharmaceutical preparations containing cyclodextrin derivatives |
US4596795A (en) * | 1984-04-25 | 1986-06-24 | The United States Of America As Represented By The Secretary, Dept. Of Health & Human Services | Administration of sex hormones in the form of hydrophilic cyclodextrin derivatives |
US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
KR0166088B1 (ko) * | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
JPH07165616A (ja) * | 1993-12-09 | 1995-06-27 | Hisamitsu Pharmaceut Co Inc | シクロデキストリンの複合組成物及び複合化法 |
US6011029A (en) * | 1996-02-26 | 2000-01-04 | Bristol-Myers Squibb Company | Inhibitors of farnesyl protein transferase |
JPH1067639A (ja) * | 1996-08-26 | 1998-03-10 | Shiseido Co Ltd | ビタミンe−ビタミンcリン酸ジエステル/シクロデキストリン包接物及び該包接物を配合した皮膚外用剤 |
-
1999
- 1999-12-21 RU RU2001118265/04A patent/RU2230062C2/ru not_active IP Right Cessation
- 1999-12-21 BR BR9916566-0A patent/BR9916566A/pt not_active Application Discontinuation
- 1999-12-21 CA CA002359646A patent/CA2359646C/en not_active Expired - Fee Related
- 1999-12-21 NZ NZ511995A patent/NZ511995A/en unknown
- 1999-12-21 CN CNB998157074A patent/CN1219517C/zh not_active Expired - Fee Related
- 1999-12-21 CZ CZ20012601A patent/CZ20012601A3/cs unknown
- 1999-12-21 UA UA2001085843A patent/UA67825C2/uk unknown
- 1999-12-21 IL IL14402599A patent/IL144025A/en not_active IP Right Cessation
- 1999-12-21 TR TR2001/02109T patent/TR200102109T2/tr unknown
- 1999-12-21 EE EEP200100382A patent/EE200100382A/xx unknown
- 1999-12-21 PL PL99366338A patent/PL195280B1/pl not_active IP Right Cessation
- 1999-12-21 WO PCT/US1999/030424 patent/WO2000042849A1/en active IP Right Grant
- 1999-12-21 SK SK960-2001A patent/SK9602001A3/sk unknown
- 1999-12-21 KR KR1020017009131A patent/KR100708360B1/ko not_active IP Right Cessation
- 1999-12-21 EP EP99967470A patent/EP1143796A4/en not_active Withdrawn
- 1999-12-21 AU AU23740/00A patent/AU772204B2/en not_active Ceased
- 1999-12-21 HU HU0105160A patent/HUP0105160A3/hu unknown
- 1999-12-21 ID IDW00200101596A patent/ID30139A/id unknown
- 1999-12-21 JP JP2000594323A patent/JP2002535253A/ja active Pending
- 1999-12-21 GE GEAP19995955A patent/GEP20043214B/en unknown
- 1999-12-31 MY MYPI99005834A patent/MY119700A/en unknown
-
2000
- 2000-01-14 TW TW089100557A patent/TWI232752B/zh not_active IP Right Cessation
- 2000-01-17 US US09/483,840 patent/US6218375B1/en not_active Expired - Lifetime
- 2000-01-18 CO CO00002434A patent/CO5160253A1/es unknown
- 2000-01-20 AR ARP000100255A patent/AR022323A1/es unknown
- 2000-01-21 UY UY25986A patent/UY25986A1/es unknown
- 2000-01-21 UY UY25987A patent/UY25987A1/es not_active Application Discontinuation
- 2000-01-21 PE PE2000000046A patent/PE20001419A1/es not_active Application Discontinuation
-
2001
- 2001-05-29 ZA ZA200104416A patent/ZA200104416B/en unknown
- 2001-06-21 LT LT2001064A patent/LT4893B/lt not_active IP Right Cessation
- 2001-07-03 BG BG105666A patent/BG105666A/xx unknown
- 2001-07-04 LV LVP-01-101A patent/LV12712B/en unknown
- 2001-07-20 NO NO20013585A patent/NO20013585L/no not_active Application Discontinuation
-
2002
- 2002-01-08 HK HK02100115.8A patent/HK1038865A1/zh unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TR200102109T2 (tr) | Ras-farnesiltransferazı inhibitörü ve sülfobütileter-7-ß-siklodekstrin veya 2-hidroksipropil-ß-siklodekstrin kompleksi ve metod. | |
AU2910600A (en) | Phenyl urea and phenyl thiourea derivatives | |
UA41247C2 (uk) | Похідні n-фенілпіразолу | |
HUP0003355A2 (hu) | Tieno[2,3-d]pirimidindion-származékok és ezeket tartalmazó gyógyszerkészítmények, eljárás előállításukra és alkalmazásuk | |
MY119238A (en) | 8-quinolinzanthine and 8-isoquinolinxanthine derivatives as pde 5 inhibitors | |
MY118904A (en) | 4-oxo-1, 4-dihydro-3-quinolinecarboxamides as antiviral agents | |
YU40799A (sh) | Pirazinska jedinjenja | |
NO934792L (no) | Xantinderivater | |
HUP0001046A2 (hu) | Ftálazin-származékok angiogenezis-gátló hatással | |
CA2074853A1 (en) | 2-aralkoxy and 2-alkoxy adenosine derivatives as coronary vasodilators and antihypertensive agents | |
DK0590919T3 (da) | Terapeutiske midler mod Parkinsons sygdom | |
CA2328780A1 (en) | Dihydropyrimidines | |
CA2188690A1 (en) | Selective thrombin inhibitors | |
ES2012646A6 (es) | Un procedimiento para la preparacion de derivados de piridazinona. | |
ATE291018T1 (de) | Pyrazol verbindungen und ihre verwendung | |
IT1315267B1 (it) | Derivati di 2-(1h-indol-3-il)-2-oxo-acetammidi ad attivita'antitumorale | |
MY129935A (en) | Dihydropyridine derivatives useful in antitumor therapy | |
BG101601A (en) | Pharmaceutical piperazine compounds | |
BG103735A (en) | Method for the preparation of substituted thiazolidindions | |
NZ334030A (en) | Synthesis of bisindolylmalimides | |
TW350838B (en) | Quinoline derivatives | |
EP0315434A3 (en) | Pyridoxal hydrazone derivatives their production and use and pharmaceutical compositions containing the same | |
KR970702848A (ko) | 아릴피페리딘 및 아릴피페라진 유도체 및 이를 함유하는 약제(Arylpiperidine and arylpiperazine derivatives and drugs containing the same) | |
TW325463B (en) | 4-Aminobenzoylguanidine-derivatives | |
ATE195728T1 (de) | Pyridinderivate als hydroxylase- und lyase- inhibitoren |